Martin Ursli
Overview
Explore the profile of Martin Ursli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
14
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ullah S, Ursli M, Fuhr U, Wiesholzer M, Kussmann M, Poeppl W, et al.
Perit Dial Int
. 2023 May;
43(5):402-410.
PMID: 37131320
Background: Meropenem is a second-line agent for the treatment of peritoneal dialysis-associated peritonitis (PD peritonitis), while information on pharmacokinetics (PK) of intraperitoneal (i.p.) meropenem is limited in this patient group....
2.
Ursli M, Zierfuss B, Grigassy T, Pesau G, Koppensteiner R, Schernthaner G, et al.
Atherosclerosis
. 2021 Dec;
341:7-12.
PMID: 34929561
Background And Aims: Galectin-3 (Gal-3) is a biomarker involved in fibrosis and vascular inflammation. Gal-3 has been linked to chronic kidney disease (CKD) and patients with peripheral artery disease (PAD)....
3.
Odler B, Windpessl M, Krall M, Steiner M, Riedl R, Hebesberger C, et al.
Front Immunol
. 2021 Nov;
12:760708.
PMID: 34777374
Objective: To characterize the incidence, type, and risk factors of severe infections (SI) in patients with autoimmune kidney diseases treated with rituximab (RTX). Methods: We conducted a multicenter retrospective cohort...
4.
Hobaus C, Ursli M, Yussef S, Wrba T, Koppensteiner R, Schernthaner G
Vasc Med
. 2021 Jan;
26(1):11-17.
PMID: 33448911
Soluble urokinase-type plasminogen activator receptor (suPAR) is associated with chronic kidney disease (CKD) severity and peripheral artery disease (PAD). We hypothesize an association of PAD severity and suPAR in patients...
5.
Tobudic S, Prager I, Kussmann M, Obermuller M, Ursli M, Zeitlinger M, et al.
Sci Rep
. 2020 Feb;
10(1):1788.
PMID: 32019947
The preferable route for treatment of peritoneal dialysis related peritonitis remains the intraperitoneal administration of antibiotics admixed to peritoneal dialysis fluids. It is important to know whether the administered drug...